View source for Company:Takeda Pharmaceutical Company

{{short description|Japanese pharmaceutical company}}
{{Infobox company
| name = Takeda Pharmaceutical Company Limited<ref name="companyname">{{Cite web|url=https://www.takeda.com/who-we-are/company-information/company-facts/|title=Company Facts &#124; Takeda|website=www.takeda.com}}</ref>
| native_name = 武田薬品工業株式会社
| native_name_lang = ja
| romanized_name = Takeda Yakuhin Kōgyō kabushiki gaisha
| former_name = Chobei Takeda & Co., Ltd. (1925–1943)<br />Takeda Pharmaceutical Industries, Ltd. (English name only 1943–1961)<br />Takeda Chemical Industries, Ltd. (English name only 1961–2004)<ref>{{Cite web|url=https://www.takeda.com/who-we-are/company-information/history/foundation-modernization/|title = The History of Takeda – 1781 to 1944 &#124; Takeda}}</ref>
| logo = Logo Takeda.svg
| image = Takeda global headquarters.jpg
| image_size = 250px
| image_caption = Global headquarters in Nihonbashi
| type = [[Finance:Public company|Public]] [[Finance:Kabushiki gaisha|KK]]
| traded_as = {{unbulleted list|{{Tyo|4502}}|{{NAG|4502}}|{{Fukuoka Stock Exchange|4502}}|{{NYSE|TAK}}|Nikkei 225 component (TYO)|TOPIX Core30 component (TYO)}}
| foundation = Doshomachi, Osaka, Japan ({{start date and age|1781|06|12|df=yes}})
| founder = Chobei Takeda I
| location_city = Nihonbashi, Chuo, Tokyo
| location_country = Japan
| key_people = Yasuchika Hasegawa<br /><small>([[Social:Chairman#Public corporations|Chairman of the Board]])</small><br />Christophe Weber<ref>{{cite news |url=https://www.reuters.com/article/takeda-pharma-ceo-idUSL4N0W62AD20150304 |title=Japan drugmaker Takeda says Christophe Weber to become CEO April 1 |author=Chris Gallagher |editor=Muralikumar Anantharaman |publisher={{wipe|Reuters}} |date=2015-03-15 |access-date=2015-04-20}}</ref><br /><small>([[Social:President (corporate title)|President]] & [[Company:CEO|CEO]])</small>
| industry = Pharmaceuticals
| revenue = {{increase}} {{JPY|4.03&nbsp;trillion}} ([[Physics:Fiscal year|FY]] 2022)<ref name="Financial Results" group="*">{{cite web|title=Financial Results for Fiscal 2023|url=https://assets-dam.takeda.com/raw/upload/v1683776005/legacy-dotcom/siteassets/system/investors/report/quarterlyannouncements/fy2022/qr2022_q4_f_en.pdf|publisher=Takeda Pharmaceutical Company Limited|access-date=December 27, 2023|date=May 11, 2023}}</ref>
| operating_income = {{increase}} {{JPY|490.51&nbsp;billion}} (FY 2022)<ref name="Financial Results" group="*" />
| net_income = {{increase}} {{JPY|317.02&nbsp;billion}} (FY 2022)<ref name="Financial Results" group="*" />
| assets = {{increase}} {{JPY|13.96&nbsp;trillion}} (FY 2022)<ref name="Financial Results" group="*" />
| equity = {{increase}} {{JPY|6.35&nbsp;trillion}} (FY 2022)<ref name="Financial Results" group="*" />
| owners = {{plainlist|
* Nippon Life (2.24%)<ref name="takeda.com">{{Cite web|url=https://www.takeda.com/investors/stock-and-shares/|title = Share Data &#124; Takeda}}</ref>
* [[Company:BNY Mellon|BNY Mellon]] (5.39%)<ref name="takeda.com"/>
* [[Company:JPMorgan Chase|JPMorgan Chase]] (3.50%)<ref name="takeda.com"/>
* [[Company:State Street Corporation|State Street Corporation]] (1.50%)}}
| num_employees = {{plainlist|
* 49,578 (2019)
* 18,378 in United States <ref>{{Cite web|url=https://www.greatplacetowork.com/certified-company/1121528|title = Working at Takeda Pharmaceuticals NA}}</ref>
* 5,350 in Japan<ref>{{Cite web|url=https://asia.nikkei.com/Business/Pharmaceuticals/Takeda-offers-early-retirement-to-workers-as-young-as-30|title=Takeda offers early retirement to workers as young as 30|website=Nikkei Asia}}</ref>}}
| homepage = {{URL|https://www.takeda.com}}
| footnotes = {{reflist|group=*}}
}}

The {{Nihongo|'''Takeda Pharmaceutical Company Limited'''<ref name="companyname"/>|武田薬品工業株式会社|Takeda Yakuhin Kōgyō kabushiki gaisha}} {{IPA-ja|takeꜜda jakɯçiŋ koꜜːɡʲoː|}} is a Japanese [[Finance:Multinational corporation|multinational]] [[Medicine:Pharmaceutical industry|pharmaceutical]] company, with partial American and British roots. It is the third largest pharmaceutical company in [[Earth:Asia|Asia]], behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with [[Company:Shire (pharmaceutical company)|Shire]]). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year.<ref>{{cite web|title=Financial Results for Fiscal 2012|url=http://www.takeda.com/investor-information/files/qr2012_full_f_en.pdf|publisher=Takeda Pharmaceutical Company Limited|access-date=2013-06-13|date=2013-05-09}}</ref> The company is focused on [[Medicine:Oncology|oncology]], rare diseases, [[Biology:Neuroscience|neuroscience]], [[Medicine:Gastroenterology|gastroenterology]], plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, {{wipe|Osaka}}, and it has an office in Nihonbashi, Chuo, [[Place:Tokyo|Tokyo]].<ref>"[http://www.takeda.com/contact/ FAQ]." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Q : Where is Takeda located? A : The Head Office is located in Osaka, Japan, and the Tokyo Head Office is located in Tokyo, Japan."</ref><ref>"[http://www.takeda.com/about-takeda/overview/article_56.html Overview]." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Headquarters Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645" and "Tokyo Head Office 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668"</ref> In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.<ref>{{Cite news|url=http://archive.fortune.com/magazines/fortune/best-companies/2012/full_list/|title=100 Best Companies to Work For 2012|date=2012-02-06|work=Fortune|access-date=2018-03-29}}</ref> As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.<ref>{{Cite web|title=Christophe Weber|url=https://www.takeda.com/who-we-are/company-information/executive-leadership/christophe-weber/|website=Takeda}}</ref>

== History ==
{{organize section|date=October 2021}}

=== Founding and initial acquisitions (1781-2010) ===
[[Image:Takeda-Midosuji-Bldg-01.jpg|right|thumb|Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan]]

Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925.<ref>{{Cite web|last=Du|first=Lisa|date=2018-12-12|title=Daring Deal by French CEO Sets Japan's Takeda on Global Path|url=https://www.bloomberg.com/news/articles/2018-12-12/daring-deal-by-french-ceo-sets-japan-s-takeda-on-global-path|access-date=2020-02-20|website=Bloomberg.com}}</ref>

One of the firm's mainstay drugs is Actos ([[Chemistry:Pioglitazone|pioglitazone]]), a compound in the thiazolidinedione class of drugs used in the treatment of [[Medicine:Diabetes mellitus type 2|type 2 diabetes]]. It was launched in 1999.<ref>{{Cite web|url=https://news.bloomberglaw.com/mergers-and-antitrust/immediate-actos-appeal-will-resolve-uncertainty-takeda-says|title=Immediate Actos Appeal Will Resolve Uncertainty, Takeda Says|website=news.bloomberglaw.com|language=en|access-date=2020-02-20}}</ref>

In February 2005, Takeda acquired San Diego, {{wipe|California}}, based Syrrx, a company specializing in high-throughput [[Physics:X-ray crystallography|X-ray crystallography]], for US$270 million.<ref>{{Cite web|url=https://www.latimes.com/archives/la-xpm-2005-feb-08-fi-syrxx8-story.html|title=Japan's Takeda to Acquire Syrrx|date=2005-02-08|website=Los Angeles Times|language=en-US|access-date=2020-02-20}}</ref>

In February 2008, Takeda acquired the Japanese operations of [[Company:Amgen|Amgen]] and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market.<ref>{{cite web|url=http://www.marketwatch.com/story/takeda-amgen-in-exclusive-tie-up-for-japanese-market |title=Takeda, Amgen in exclusive tie-up for Japanese market |publisher=MarketWatch |date=2008-02-04 |access-date=2010-09-18}}</ref>  In April, Takeda acquired Millennium Pharmaceuticals of Cambridge, {{wipe|Massachusetts}}, a company specializing in [[Medicine:Cancer|cancer]] drug research, for US$8.8 billion.<ref name=":1">{{Cite news|url=https://www.reuters.com/article/us-millennium-idUST18218420080410|title=Takeda to buy Millennium Pharma for $8.8 billion|date=2008-04-10|work=Reuters|access-date=2020-02-20|language=en}}</ref> The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary.<ref name=":1" /> In May, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.<ref>{{Cite web|url=https://www.bioworld.com/articles/354179-alnylam-signs-potential-1b-rnai-agreement-with-takeda?v=preview|title=Alnylam Signs Potential $1B RNAi Agreement with Takeda|website=bioworld.com|language=en|access-date=2020-02-20}}</ref>

=== Further expansion and research (2011-present) ===
In September 2011, Takeda acquired Nycomed for [[Finance:Euro|€]]9.6 billion.<ref>{{cite web|url=https://dealbook.nytimes.com/2011/05/19/takeda-to-buy-nycomed-for-13-7-billion/|title=Takeda to Buy Nycomed for $13.7 Billion|last=Dealbook|date=2011-05-19|website=DealBook|language=en|access-date=2020-02-20}}</ref>

In May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for [[Finance:Brazilian real|R$]]540 million.<ref>{{cite web|author=Hirschler, Ben|date=2012-05-25|title=Farmacêutica Takeda comprará Multilab por até R$ 540 mi|url=http://exame.abril.com.br/negocios/empresas/aquisicoes-fusoes/noticias/farmaceutica-takeda-comprara-multilab-por-ate-r-540-mi|access-date=2013-01-27|work=Grupo Abril|publisher=Exame|language=pt}}</ref> In June, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million.<ref>{{Cite web|url=https://www.pharmaceutical-technology.com/uncategorised/newstakeda-to-acquire-url-pharma-for-800m/|title=Takeda to acquire URL Pharma for $800m|date=11 April 2012|language=en-GB|access-date=2020-02-20}}</ref>

In September 2014, Takeda announced it would team up with [[Company:BioMotiv|BioMotiv]] to identify and develop new compounds over a five-year period, worth approximately US$25 million.<ref>{{cite news |url = http://www.genengnews.com/gen-news-highlights/takeda-biomotiv-launch-25m-drug-development-partnership/81250399/?kwrd=Takeda|title = Takeda, BioMotiv Launch $25M Drug Development Partnership|date = 2014-09-26|work = Genetic Engineering & Biotechnology News|publisher = Mary Ann Liebert, Inc.|access-date = 2015-04-23}}</ref> On 30 September 2014, Takeda announced it would expand a collaboration with MacroGenics, valued up to US$1.6 billion. The collaboration focused on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and [[Biology:CD79B|CD79B]], and is indicated for [[Medicine:Lupus|lupus]] and [[Medicine:Rheumatoid arthritis|rheumatoid arthritis]].<ref>{{cite news |url = http://www.genengnews.com/gen-news-highlights/takeda-macrogenics-launch-up-to-1-6b-expansion-of-dart-collaboration/81250413/|title = Takeda, MacroGenics Launch Up to $1.6B Expansion of DART Collaboration|date = 2014-09-30|work = Genetic Engineering & Biotechnology News|publisher = Mary Ann Liebert, Inc.|access-date = 2015-04-23}}</ref>

In 2015, Takeda sold its respiratory drugs business to [[Company:AstraZeneca|AstraZeneca]] for $575 million (about £383 million), which included [[Chemistry:Roflumilast|roflumilast]] and [[Chemistry:Ciclesonide|ciclesonide]].<ref>Julia Bradshaw for The Daily Telegraph, 16 December 2015.  [https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/12052991/AstraZeneca-to-buy-Takedas-lung-business-for-383m.html  ''AstraZeneca to buy Takeda's lung business for £383m''].Accessed: 17 December 2015.</ref> On November, the U.S. [[Organization:Food and Drug Administration|Food and Drug Administration]] approved [[Chemistry:Ixazomib|Ixazomib]] developed by Takeda for use in combination with [[Chemistry:Lenalidomide|lenalidomide]] and [[Biology:Dexamethasone|dexamethasone]] for the treatment of [[Medicine:Multiple myeloma|multiple myeloma]] after at least one prior therapy.<ref>{{Cite web|url=https://www.drugs.com/history/ninlaro.html|title=Ninlaro (ixazomib) FDA Approval History|website=Drugs.com|language=en|access-date=2020-02-20}}</ref>

In December 2016, the company spun out its neuroscience research division into Cerevance, a joint venture along with Lightstone Ventures.<ref>{{Cite web | url=http://www.genengnews.com/gen-news-highlights/takeda-spins-out-research-team-into-neuroscience-startup/81253491 | title=Takeda Spins Out Research Team into Neuroscience Startup| date=2016-12-02}}</ref>

In February 2017, Takeda acquired Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions.<ref>{{Cite web | url=http://www.genengnews.com/gen-news-highlights/takeda-to-acquire-ariad-pharmaceuticals-for-52b/81253671 | title=Takeda to Acquire ARIAD Pharmaceuticals for $5.2B| date=2017-01-09}}</ref>

In January 2018, the company acquired stem cell therapy developer TiGenix for up to €520 million ($632 million).<ref>{{Cite web | url=https://www.genengnews.com/gen-news-highlights/takeda-to-acquire-tigenix-for-520m/81255343 | title=Takeda to Acquire TiGenix for €520M| date=2018-01-05}}</ref>

In January 2019, Takeda acquired [[Company:Shire (pharmaceutical company)|Shire]] for more than {{US$|50 billion}}.<ref>{{Cite news|url=https://www.bloomberg.com/news/articles/2018-05-08/takeda-inks-62-billion-deal-to-buy-shire-for-cash-and-shares|title=Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire|last1=Du|first1=Lisa|date=8 May 2018|access-date=6 July 2019|publisher=Bloomberg|last2=Takahashi|first2=Maiko|language=en|url-access=subscription}}</ref><ref>{{Cite journal|last=Philippidis|first=Alex|date=1 July 2019|title=Top 10 M&A Deasl of January&mdash;June 2019|url=https://www.genengnews.com/a-lists/top-10-ma-deals-of-january-june-2019/|journal=Genetic Engineering & Biotechnology News|quote=And it didn't include earlier-announced deals completed in 2019, such as Takeda Pharmaceutical's £46 billion ($58.6 billion) purchase of Shire.}}</ref> In October, Takeda announced it had sold a portfolio of over-the-counter and prescription medicines in the [[Place:Middle East|Middle East]] and [[Earth:Africa|Africa]] to Swiss pharmaceuticals company Acino International for more than $200 million.<ref>{{Cite news|url=https://www.reuters.com/article/us-takeda-pharma-divestiture-idUSKBN1WU0TZ|title=Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino|date=2019-10-15|work=Reuters|access-date=2019-10-15|language=en}}</ref><ref>{{Cite web|url=https://www.fiercepharma.com/pharma/takeda-wraps-30-emerging-markets-drugs-200m-selloff-to-swiss-pharma-acino|title=Takeda wraps 30 emerging markets drugs in $200M selloff to Swiss pharma Acino|website=FiercePharma|date=15 October 2019|language=en|access-date=2019-10-15}}</ref>

In January 2020, Takeda announced a research partnership with the [[Organization:Massachusetts Institute of Technology|Massachusetts Institute of Technology]] (MIT) to advance discoveries in [[Artificial intelligence|artificial intelligence]] and health. The MIT-Takeda Program is housed in the MIT Jameel Clinic, and is led by Professor James J. Collins, with a steering committee led by Professor Anantha P. Chandrakasan, dean of the MIT School of Engineering, and Anne Heatherington, senior vice president and head of Data Sciences Institute (DSI) at Takeda.<ref>{{Cite web|title=MIT School of Engineering and Takeda join to advance research in artificial intelligence and health|url=https://news.mit.edu/2020/mit-school-engineering-takeda-join-to-advance-artificial-intelligence-health-research-0106|access-date=2020-11-13|website=MIT News {{!}} Massachusetts Institute of Technology|language=en}}</ref><ref>{{Cite web|last=analytica|first=TOKYO|date=2020-01-07|title=武田薬品とMITがAI研究を推進するプログラムを発表 {{!}} 医療とAIのニュース・最新記事 - The Medical AI Times|url=https://aitimes.media/2020/01/07/3892/|access-date=2020-11-13|website=The AI Times|language=ja}}</ref><ref>{{Cite web|date=2020-01-06|title=MIT, Takeda collaborate on new healthcare AI applications|url=https://www.healthcareitnews.com/news/mit-takeda-collaborate-new-healthcare-ai-applications|access-date=2020-11-13|website=Healthcare IT News|language=en}}</ref> In March 2020, Takeda announced that it has entered into an exclusive agreement to divest a portfolio of non-core products in Latin America to Hypera S.A. for a total value of $825 million.<ref>{{Cite web|url=https://www.biospace.com/article/takeda-agrees-to-divest-select-otc-and-non-core-assets-in-latin-america-to-hypera-pharma-for-825-million-usd/|title=Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD|website=BioSpace|language=en-US|access-date=2020-03-03}}</ref>

In March 2021, the company announced it would acquire Maverick Therapeutics, Inc. and its two major programs TAK-186 (MVC-101) in trials for the treatment of [[Biology:Epidermal growth factor receptor|EGFR]]-expressing tumours and TAK-280 (MVC-280) for use in the treatment of patients with B7H3-expressing tumors.<ref>{{Cite news|url=https://www.biospace.com/article/takeda-to-acquire-maverick-therapeutics-to-advance-t-cell-engager-therapies-for-solid-tumors-and-expand-novel-immuno-oncology-portfolio/|title=Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio|website=BioSpace}}</ref> In October, they acquired GammaDelta Therapeutics and its gamma delta (γδ) [[Biology:T cell|T cell]] immunotherapy programme.<ref>{{Cite web|url=https://www.biospace.com/article/takeda-snaps-up-partner-gammadelta-to-bolster-oncology-pipeline-/?s=79|title = Takeda Snaps up Partner GammaDelta to Bolster Oncology Pipeline}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/takeda-to-acquire-gammadelta-therapeutics-to-accelerate-development-of-allogeneic-γδt-cell-therapies-addressing-solid-tumors/|title=Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors|website=BioSpace}}</ref>

In January 2022, Takeda announced it would exercise its option to acquire Adaptate Biotherapeutics and its antibody-based γδ T cell technology, reuniting Adaptate and its former parent company, GammaDelta Therapeutics, in a single organisation.<ref>{{Cite web|url=https://www.biospace.com/article/takeda-augments-io-portfolio-with-third-build-to-buy-acquisition-in-a-year-/|title=Takeda Augments IO Portfolio with Third Build-to-Buy Acquisition in a Year|website=BioSpace}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/takeda-to-acquire-adaptate-biotherapeutics-to-develop-novel-gamma-delta-γδ-t-cell-engager-therapies-targeting-solid-tumors/|title=Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors|website=BioSpace}}</ref> In December of the same year, the company announced it would acquire Nimbus Lakshmi, Inc. and its lead compound NDI-034858 which is an allosteric TYK2 inhibitor, from Nimbus Therapeutics, LLC for up to $6 billion.<ref>{{Cite web|url=https://www.biospace.com/article/takeda-to-acquire-nimbus-therapeutics-highly-selective-allosteric-tyk2-inhibitor-to-address-multiple-immune-mediated-diseases/|title=Takeda to Acquire Nimbus Therapeutics' Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases|website=BioSpace}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/takeda-drops-6b-for-nimbus-therapeutics-tyk2-autoimmune-drug/|title=Takeda Bets $4B Upfront on Nimbus' TYK2 Inhibitor|website=BioSpace}}</ref>

=== TAP Pharmaceuticals (1977-2008) ===
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with [[Organization:Abbott Laboratories|Abbott Laboratories]] called TAP Pharmaceuticals.<ref>{{Cite web|date=2017-07-18|title=Takeda shrinks its Deerfield workforce, as it adds in Boston|url=https://www.chicagobusiness.com/article/20170718/NEWS03/170719872/takeda-shrinks-suburban-chicago-workforce-as-it-adds-in-boston|access-date=2020-02-20|website=Crain's Chicago Business|language=en}}</ref> Through TAP Pharmaceuticals Takeda and Abbott launched [[Chemistry:Medication#Blockbuster drug|blockbuster]] drugs Lupron ([[Chemistry:Leuprorelin|leuprorelin]]), in 1985,<ref>{{cite news|last1=Japson|first1=Bruce|date=Apr 29, 2001|title=The Lupron loophole: Cancer drug strikes it rich|work=Chicago tribune|url=https://www.chicagotribune.com/news/ct-xpm-2001-04-29-0104290332-story.html|access-date=19 June 2021}}</ref> then Prevacid ([[Chemistry:Lansoprazole|lansoprazole]]), in 1995.<ref>{{Cite web|title=Takeda Pharmaceutical to Pay Abbott Laboratories up to $1.5B in Venture Split|url=https://www.fiercebiotech.com/biotech/takeda-pharmaceutical-to-pay-abbott-laboratories-up-to-1-5b-venture-split|access-date=2020-02-20|website=FierceBiotech|date=20 March 2008|language=en}}</ref>

In 2001, TAP's illegal marketing of Lupron resulted in both civil and criminal charges by the U.S. Department of Justice and the Illinois attorney general for federal and state medicare fraud. TAP was fined $875 million, then reported as the largest pharmaceutical settlement in history.<ref>{{cite news|last1=Petersen|first1=Melody|date=Oct 4, 2001|title=2 Drug Makers to Pay $875 Million to Settle Fraud Case|work=The New York Times|url=https://www.nytimes.com/2001/10/04/business/2-drug-makers-to-pay-875-million-to-settle-fraud-case.html|access-date=June 19, 2021}}</ref><ref name="DOJ">{{cite web|date=Oct 3, 2001|title=Press Release: TAP Pharmaceutical Products Inc. and Seven Others Charged with Health Care Crimes|url=https://www.justice.gov/archive/opa/pr/2001/October/513civ.htm|access-date=June 19, 2021|publisher=US Department of Justice}}</ref>

In March 2008, Takeda and [[Organization:Abbott Laboratories|Abbott Laboratories]] announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals.<ref>{{Cite web|date=2008-03-19|title=Abbott, Takeda to end joint venture|url=https://www.chicagobusiness.com/article/20080319/NEWS03/200028640/abbott-takeda-to-end-joint-venture|access-date=2020-02-20|website=Crain's Chicago Business|language=en}}</ref> The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff.<ref name=":0">{{Cite news|last=Wang|first=Shirley S.|date=2008-03-20|title=Abbott, Takeda to End Joint Venture|language=en-US|work=Wall Street Journal|url=https://www.wsj.com/articles/SB120596276402549819|access-date=2020-02-20|issn=0099-9660}}</ref> Takeda received rights to Prevacid and TAP's pipeline candidates.<ref name=":0" /> The move also increased Takeda's headcount by 3,000 employees.<ref>{{cite web|last=Marrazzo|first=Amanda|date=2008-05-15|title=Featured Articles From The Chicago Tribune|url=http://archives.chicagotribune.com/2008/mar/20/business/chi-thu_abbott-takedamar20|access-date=2010-09-18|publisher=Archives.chicagotribune.com}}</ref>

== Acquisition history ==
{{Tree list}}
*'''Takeda Pharmaceutical Company''' <small>(Est. 1781)</small>
**Syrrx <small>(Acq 2005)</small>
**Millennium Pharmaceuticals <small>(Acq 2008)</small>
***COR Therapeutics <small>(Acq 2002)</small>
***Cambridge Discovery Chemistry <small>(Acq 2000)</small>
***Leukosite <small>(Acq 1999)</small>
**Nycomed <small>(Acq 2011)</small>
***Altana Pharma <small>(Pharmaceuticals div, Acq 2007)</small>
***Bradley Pharmaceuticals <small>(Acq 2007)</small>
**URL Pharma <small>(Acq 2012)</small>
**Multilaba <small>(Acq 2012)</small>
**Cerevance <small>(Neuroscience div, Spun off 2016)</small>
**Ariad Pharmaceuticals <small>(Acq 2017)</small>
**TiGenix <small>(Acq 2018)</small>
**Shire plc <small>(Founded 1986, Acq 2019)</small>
***Pharmavene <small>(Acq 1997)</small>
***Richwood Pharmaceutical Company <small>(Acq 1997)</small>
***Biochem Canada <small>(Acq 2001)</small>
***Transkaryotic Therapeutics <small>(Acq 2005)</small>
***New River Pharmaceuticals Inc <small>(Acq 2007)</small>
***Jerini <small>(Acq 2008)</small>
***Movetis <small>(Acq 2012)</small>
***Advanced BioHealing <small>(Acq 2011)</small>
***FerroKin BioSciences <small>(Acq 2012)</small>
***Lotus Tissue Repair, Inc <small>(Acq 2013)</small>
***Premacure AB <small>(Acq 2013)</small>
***SARcode Bioscience Inc <small>(Acq 2013)</small>
***[[Company:ViroPharma|ViroPharma]] <small>(Founded 1994, Acq 2013)</small>
****Lev Pharmaceuticals <small>(Acq 2008)</small>
***Fibrotech <small>(Acq 2014)</small>
***Lumena <small>(Acq 2014)</small>
***NPS Pharmaceuticals <small>(Acq 2015)</small>
***Meritage Pharma <small>(Acq 2015)</small>
***Foresight Biotherapeutics <small>(Acq 2015)</small>
***Dyax <small>(Acq 2015)</small>
***Baxalta <small>(Acq 2016)</small>
**PvP Biologics, Inc. <small>(Acq 2020)</small>
**Maverick Therapeutics, Inc. <small>(Acq 2021)</small>
**GammaDelta Therapeutics <small>(Acq 2021)</small>
**Adaptate Biotherapeutics <small>(Acq 2022)</small>
**Nimbus Lakshmi, Inc. <small>(Acq 2022)</small>
{{Tree list/end}}

== Divestments ==
In May 2019, Takeda sold its Xiidra dry-eye drug business to [[Company:Novartis|Novartis]] for $5.3 billion, $3.4 billion upfront and up-to $1.9 billion in sales milestones.<ref>{{Cite web|title=Novartis to buy Takeda's eyedrop unit for $5.3bn|url=https://asia.nikkei.com/Business/Business-deals/Novartis-to-buy-Takeda-s-eyedrop-unit-for-5.3bn|access-date=2020-06-12|website=Nikkei Asian Review|language=en-GB}}</ref><ref name="endpts.com">{{Cite web|title=Takeda continues post-Shire selloff, inching closer to $10B goal|url=https://endpts.com/takeda-continues-post-shire-selloff-inching-closer-to-10b-goal/|access-date=2020-06-12|website=Endpoints News|language=en}}</ref>

In November 2019, Takeda entered an agreement to sell its over-the-counter and prescription drugs businesses in Russia, Georgia, Armenia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan to Stada Arzneimittel for $660 million.<ref>{{Cite web|title=Takeda sells Russian assets in $660m deal to cut Shire debt|url=https://asia.nikkei.com/Business/Business-deals/Takeda-sells-Russian-assets-in-660m-deal-to-cut-Shire-debt|access-date=2020-06-12|website=Nikkei Asian Review|language=en-GB}}</ref>

In June 2020, Takeda announced that it was divesting 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea's Celltrion in a deal worth $278 million.<ref name="endpts.com"/><ref>{{Cite web|title=Takeda sells 18 drugs to South Korea's Celltrion in $278m deal|url=https://asia.nikkei.com/Business/Business-deals/Takeda-sells-18-drugs-to-South-Korea-s-Celltrion-in-278m-deal|access-date=2020-06-12|website=Nikkei Asian Review|language=en-GB}}</ref><ref>{{Cite news|date=2020-06-11|title=BRIEF-Takeda Pharmaceutical Enters Into Agreement To Divest Portfolio Of Select Non-Core OTC And Prescription Pharmaceutical Products|language=en|work=Reuters|url=https://www.reuters.com/article/brief-takeda-pharmaceutical-enters-into-idUSFWN2DO08Z|access-date=2020-06-12}}</ref><ref>{{Cite news|date=2020-06-11|title=Takeda to Divest OTC and Select Non-core Assets in Asia Pacific to Celltrion for up to $278 Million USD {{!}} Financial Post|newspaper=Financialpost|url=https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/takeda-to-divest-otc-and-select-non-core-assets-in-asia-pacific-to-celltrion-for-up-to-278-million-usd|access-date=2020-06-12|language=en-CA}}</ref>

Also in 2020, Takeda sold [[Chemistry:TachoSil|TachoSil]] to Corza Health, Inc. for €350 million.<ref>{{Cite web |title=Takeda to Divest TachoSil® to Corza Health for €350 Million |url=https://www.takeda.com/newsroom/newsreleases/2020/takeda-to-divest-tachosil-to-corza-health-for-350-million |access-date=2023-04-09 |website=www.takeda.com |language=en}}</ref>

== Locations ==
Takeda operates two primary bases in Japan in {{wipe|Osaka}} and [[Place:Tokyo|Tokyo]]. Its United States subsidiary is based in Cambridge, Massachusetts, and all Global Operations outside Japan and the U.K. are based in Opfikon (Zurich), Switzerland.
The company maintains research and development sites in Japan, the United States, the United Kingdom and Singapore, with manufacturing facilities across the globe.

== Lawsuits ==
In April 2015 Takeda agreed to pay a settlement of $2.37 billion to an estimated 9,000 people who submitted claims alleging that [[Chemistry:Pioglitazone|pioglitazone]] was responsible for giving them bladder cancer. The company said the decision is expected to resolve the “vast majority” of these cases. Takeda will put the money into a settlement fund if 95 percent of plaintiffs agree to the accord, according to which each claimant would get an average $267,000. However, the exact amount for each plaintiff will be evaluated based on cumulative dosage, extent of injuries and history of smoking.<ref>{{cite web|url=https://www.nytimes.com/2015/04/29/business/takeda-agrees-to-pay-2-4-billion-to-settle-suits-over-cancer-risk-of-actos.html|title=Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos|date=29 April 2015|work=The New York Times}}</ref>  In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda hid the cancer risks of their diabetes medicine,<ref>{{cite web|url=https://www.bloomberg.com/news/articles/2014-04-07/takeda-actos-jury-awards-6-billion-in-punitive-damages|title=Takeda, Lilly Jury Awards $9 Billion Over Actos Risks|first1=Jef|last1=Feeley|first2=Kanoko|last2=Matsuyama|date=9 April 2014|website=bloomberg.com}}</ref> but the amount was later reduced to $26 million by a judge who deemed the charge excessive.<ref>{{cite web|url=http://www.ibtimes.com/japans-takeda-agrees-24b-settlement-diabetes-drug-actos-lawsuit-over-cancer-risk-1901009|title=Japan's Takeda Agrees To $2.4B Settlement In Diabetes Drug Actos Lawsuit Over Cancer Risk Allegations|website=International Business Times|date=29 April 2015}}</ref>

== Public-private engagement ==

=== Activism ===
Takeda is a corporate partner of Human Rights Campaign, a large LGBT advocacy organization.<ref>{{Cite web |date= |title=Corporate Partners |url=https://www.hrc.org/about/corporate-partners |url-status=live |archive-url=https://web.archive.org/web/20220714072833/https://www.hrc.org/about/corporate-partners |archive-date=2022-07-14 |access-date=2022-07-14 |website=Human Rights Campaign}}</ref>

==References==
{{Reflist|30em}}

==External links==


[[Category:Companies listed on the New York Stock Exchange]]

{{Sourceattribution|Takeda Pharmaceutical Company}}